Fig. 1

Construction and validation of the TICS. A Meta-analysis of the HRs of eight immune signatures. B Clinicopathological features and the expression pattern of prognostic immune signatures in training cohorts. C–F Kaplan–Meier analysis of the high- and low-TICS group in each training cohort. G Clinicopathological features and the expression pattern of immune signatures in validation cohorts. H–J Kaplan–Meier analysis of the high- and low-TICS group in each training cohort. K The time-dependent AUC and C-index of the TICS in each cohort. L The HR values of the TICS in training and validation cohorts by meta-analysis. (PSM positive surgical margin, PSA prostate specific antigen, HR hazard ratio, BCR biochemical recurrence, CI confidence interval, TCGA The Cancer Genome Atlas, AUC area under the curve.)